Paper40721981
Mitochondrial bioenergetics and networks in melanoma: an update.
Giannitti G and 4 others. Apoptosis, 2025. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Mitochondrial bioenergetics and networks in melanoma: an update. Papers, record 40721981. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40721981
- Disease
- non-small cell lung carcinoma1,066 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records7
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Diseases7
- non-small cell lung carcinomaOne of its trials lists the paper1,066 drugs, 4,857 trials
- melanomaOne of its trials lists the paper589 drugs, 1,589 trials
- hepatocellular carcinomaOne of its trials lists the paper478 drugs, 1,505 trials
- head and neck squamous cell carcinomaOne of its trials lists the paper424 drugs, 1,056 trials
- renal cell carcinomaOne of its trials lists the paper345 drugs, 801 trials
- gastroesophageal junction adenocarcinomaOne of its trials lists the paper178 drugs, 497 trials
- urogenital neoplasmOne of its trials lists the paper40 drugs, 28 trials
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Melanoma | Major topic |
| Mitochondria | Major topic |
| Energy Metabolism | Major topic |
| Skin Neoplasms | Major topic |
| Humans | |
| Apoptosis | |
| Animals |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Progetto di Eccellenza | Ministero dell'Istruzione, dell'Università e della Ricerca | PubMed | ||
| PSR2023 | Università degli Studi di Milano | PubMed |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01989585 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03311308 | A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Derived from the trial | Yes | ClinicalTrials.gov |
References165
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27086916 | Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. | Oncotarget | 2017 | https://conductscience.org/library/papers/27086916 | PubMed |
| 2 | 22295108 | A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers. | PLoS One | 2012 | https://conductscience.org/library/papers/22295108 | PubMed |
| 3 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 4 | 30625226 | Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. | PLoS One | 2019 | https://conductscience.org/library/papers/30625226 | PubMed |
| 5 | 35203350 | Mitofusin-2 Negatively Regulates Melanogenesis by Modulating Mitochondrial ROS Generation. | Cells | 2022 | https://conductscience.org/library/papers/35203350 | PubMed |
| 6 | 24997364 | The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways. | Arch Biochem Biophys | 2014 | https://conductscience.org/library/papers/24997364 | PubMed |
| 7 | 38812059 | Mitochondrial quality control in human health and disease. | Mil Med Res | 2024 | https://conductscience.org/library/papers/38812059 | PubMed |
| 8 | 10867810 | Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. | Arch Dermatol Res | 2000 | https://conductscience.org/library/papers/10867810 | PubMed |
| 9 | 27751856 | AMPK activation by GSK621 inhibits human melanoma cells in vitro and in vivo. | Biochem Biophys Res Commun | 2016 | https://conductscience.org/library/papers/27751856 | PubMed |
| 10 | 36931258 | Omics-based approaches for the systematic profiling of mitochondrial biology. | Mol Cell | 2023 | https://conductscience.org/library/papers/36931258 | PubMed |
| 11 | 25065405 | Mitochondrial dynamics regulate melanogenesis through proteasomal degradation of MITF via ROS-ERK activation. | Pigment Cell Melanoma Res | 2014 | https://conductscience.org/library/papers/25065405 | PubMed |
| 12 | 35347324 | PGC-1α induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma. | Br J Cancer | 2022 | https://conductscience.org/library/papers/35347324 | PubMed |
| 13 | 37488586 | Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37488586 | PubMed |
| 14 | 28489985 | Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. | Cell Cycle | 2017 | https://conductscience.org/library/papers/28489985 | PubMed |
| 15 | 38036770 | Mitophagy in human health, ageing and disease. | Nat Metab | 2023 | https://conductscience.org/library/papers/38036770 | PubMed |
| 16 | 38424050 | Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/38424050 | PubMed |
| 17 | 31439581 | A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31439581 | PubMed |
| 18 | 32021565 | A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products. | Cancer Cell Int | 2020 | https://conductscience.org/library/papers/32021565 | PubMed |
| 19 | 24429632 | Mitochondrial form and function. | Nature | 2014 | https://conductscience.org/library/papers/24429632 | PubMed |
| 20 | 34205414 | Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34205414 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42909325 | Mitochondrial remodeling in heart failure with reduced ejection fraction. | Front Physiol | 2026 | https://conductscience.org/library/papers/42909325 | PubMed |
| 42882458 | Redox Storm in the Tumor Microenvironment (ΤΜΕ): Multifaceted Redox Injury and Immunometabolic Reprogramming Induced by Immune Checkpoint Blockade in B16F10 Melanoma: An Ultrastructural Study of the Peritumoral Interface. | Cells | 2026 | https://conductscience.org/library/papers/42882458 | PubMed |
| 42795718 | Melanoma Intelligence: Explainable AI Reveals Histopathologic Aggressiveness as the Dominant Axis of Lymph-Node Metastasis. | J Clin Med | 2026 | https://conductscience.org/library/papers/42795718 | PubMed |
| 42737574 | Eriobotrya japonica (Loquat) Leaf Extract: An Integral In Vitro and In Ovo Approach to Antimelanoma Potential and Safety. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737574 | PubMed |
| 42653911 | The Plant Protease Inhibitor EcTI Suppresses Melanoma Progression In Vivo. | Molecules | 2026 | https://conductscience.org/library/papers/42653911 | PubMed |
| 42538580 | Phytochemical Characterization of Echeveria "Blue Curls" and Its Association With Redox-Metabolic Perturbations in Melanoma Cells. | Chem Biodivers | 2026 | https://conductscience.org/library/papers/42538580 | PubMed |
| 42353208 | Metformin Enhances 2-Aminoethyl Dihydrogen Phosphate-Induced Mitochondrial Dysfunction and Apoptosis in Melanoma Cells. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353208 | PubMed |
| 41897479 | Adipocyte-Derived Extracellular Vesicles Endow Melanoma Cells with Stem-like Traits via PGC-1α-Mediated Mitochondrial Reprogramming. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41897479 | PubMed |
| 41751850 | Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41751850 | PubMed |
| 41751773 | Onconase Induces Apoptosis in Dabrafenib-Resistant Melanoma Cell Lines Through Dysregulation of ROS Homeostasis, Antioxidant Protein Expression, and Mitochondrial Dynamics. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41751773 | PubMed |
| 41736012 | Mitophagy-driven multidimensional regulation of tumor immune evasion and context-dependent therapeutic strategies. | J Transl Med | 2026 | https://conductscience.org/library/papers/41736012 | PubMed |
| 41596686 | Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596686 | PubMed |
| 41573726 | Mitochondrial dysfunction and apoptotic signaling induced by the combined action of 2-aminoethyl dihydrogen phosphate and methyl-β-cyclodextrin in melanoma cells. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41573726 | PubMed |
| 41463339 | The Neuro-Melanoma Singularity: Convergent Evolution of Neural and Melanocytic Networks in Brain Metastatic Adaptation. | Biomolecules | 2025 | https://conductscience.org/library/papers/41463339 | PubMed |
| 41179682 | Integrating single-cell transcriptomics and whole-genome CRISPR CAS9 screen identifies a cell cluster associated with tumor dependency in triple-negative breast cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/41179682 | PubMed |
Drugs7
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| ROSIGLITAZONE | CHEMBL121 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL121 | ChEMBL |
| METFORMIN | CHEMBL1431 | Derived from the trial | 2 | https://conductscience.org/library/drugs/CHEMBL1431 | ChEMBL |
| DABRAFENIB | CHEMBL2028663 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2028663 | ChEMBL |
| TRAMETINIB | CHEMBL2103875 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2103875 | ChEMBL |
| NIVOLUMAB | CHEMBL2108738 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2108738 | ChEMBL |
| PEMBROLIZUMAB | CHEMBL3137343 | Derived from the trial | 2 | https://conductscience.org/library/drugs/CHEMBL3137343 | ChEMBL |
| NAVITOCLAX | CHEMBL443684 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL443684 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40721981
GET https://conductscience.org/api/papers/v1/40721981/references?page=2